Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173724 | 1.00 | SRC (0.56) | SRCRAB9AMAPK1POLBRECQL | |
| SCHEMBL8513394 | 0.87 | RECQL (0.59) | POLBRECQL | |
| SCHEMBL25780628 | 0.86 | SRC (0.54) | SRCRAB9AMAPK1POLBRPS6KB1 | |
| SCHEMBL354056 | 0.86 | SRC (0.60) | SRCRAB9AMAPK1POLBANPEP | |
| SCHEMBL3109722 | 0.84 | SRC (0.61) | SRCRAB9AMAPK1POLBANPEP | |
| SCHEMBL29699631 | 0.84 | SRC (0.61) | SRCRAB9AMAPK1POLBANPEP | |
| SCHEMBL8178554 | 0.83 | ANPEP (0.54) | SRCRAB9AMAPK1POLBANPEP | |
| SCHEMBL5528698 | 0.82 | PTPN7 (0.50) | SRCRAB9AMAPK1POLB | |
| SCHEMBL885310 | 0.82 | SRC (0.56) | SRCRAB9AMAPK1POLBANPEP | |
| M-Fluorobenzylguanidine SCHEMBL4335223 | 0.82 | SRC (0.49) | SRCRAB9AMAPK1POLBRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8383670-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-7906553-B2 | Substituted thiophene modulators of intracellular calcium | CALCIMEDICA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009131196-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| CN-101489551-A | Aminoindazole urea derivatives | MERCK PATENT GMBH (DE) | 2009-07-22 | — | — | CN | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002481-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1478084-A | Compounds useful in treatment of inflammatory diseases | — | 2004-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | SRC 1549/4885RAB9A 1174/4885MAPK1 2526/4885 |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | SRC 1549/4885RAB9A 1174/4885MAPK1 2526/4885 |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | SRC 1549/4885RAB9A 1174/4885MAPK1 2526/4885 |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | SRC 969/4885RAB9A 3528/4885MAPK1 594/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | SRC 4601/4885RAB9A 902/4885MAPK1 1202/4885 |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | TST, UMPS, UROD | SRC 2102/4885RAB9A 2573/4885MAPK1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.